JUBILANT LIFE SCIENCES LIMITED - 530019 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Sub.: Submission of copies of newspaper advertisements In continuation of our letter dated July 19, 2019, we enclose copies of the advertisements published on July 20, 2019, in MINT (English) and HINDUSTAN (Hindi) with respect to notice of the Board Meeting scheduled to be held on July 26, 2019. This is for information and record. Jubilant Life Sciences Ltd - 530019 - Shareholding for the Period Ended June 30, 2019
Jubilant Life Sciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2019. For more details, kindly Click here JUBILANT LIFE SCIENCES LIMITED - 530019 - Board Meeting Intimation for Intimation Of Board Meeting - July 26, 2019
JUBILANT LIFE SCIENCES LIMITEDhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/07/2019 ,inter alia, to consider and approve In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, July 26, 2019, to inter-alia consider Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2019. This is for information and record. Jubilant Life Sciences Ltd - 530019 - Schedule Of Investor Conference Call For Jubilant Life Sciences Limited - Unaudited Financial Results For The Quarter Ended June 30, 2019
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company is organising a Conference Call on July 26, 2019 after submission of the financial results for the quarter ended June 30, 2019 to the Stock Exchanges. Details of the Conference Call are attached. This is for information and record. Jubilant Life Sciences Ltd - 530019 - Jubilant Announces Price Increase Of Vitamin B3 (Niacin And Niacinamide)
Dear Sirs, We enclose a communication pertaining to Vitamin B3 price increase. This is for your kind information and record. Jubilant Life Sciences Ltd - 530019 - Statement Of Investor Complaints For The Quarter Ended June 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 1230 Name of the Signatory :- Rajiv ShahDesignation :- Company Secretary and Compliance Officer JUBILANT LIFE SCIENCES LIMITED - 530019 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that share certificate has been reported to be lost by the shareholder as stated in the attached document. The shareholder has requested for issuance of duplicate share certificate in lieu of the original. We propose to issue Duplicate Share Certificate to the shareholder on receipt of the requisite documents. We request you to caution your members not to deal in or make any transaction in these shares. This is for your information and record. Jubilant Life Sciences Ltd - 530019 - Intimation Pursuant To Regulation 50(1) And 60(2) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For Record Date And Interest Payment On Non-Convertible Debentures
Dear Sirs, We wish to inform you that payment of interest shall be made to the holders of Non-Convertible Debentures as per attached details. Record date for the payment of interest stated above shall be July 12, 2019. This is for your information and records. Jubilant Life Sciences Ltd - 530019 - Sub: Issuance Of Commercial Papers Of Rs. 40 Crore
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company has issued Commercial Papers ('CPs') of Rs. 40 Crore on June 25, 2019. Details of the same are attached. The aggregate amount of Commercial Papers (including this issue) outstanding as on date is Rs. 40 Crore. This is for your information and records. Jubilant Life Sciences Ltd - 530019 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Miller Holdings PTE Ltd